This year, the Notre Dame team primarily developed a comprehensive computational framework for rational protein engineering of GLP‑1 agonists, combining evolutionary bioinformatics with systematic experimental optimization strategies. Our work provides future iGEM teams with validated tools, methodologies, and insights for peptide hormone engineering and therapeutic protein design.
We developed and released a complete bioinformatics pipeline for analyzing GLP‑1 homologs and identifying mutation‑tolerant positions for rational protein design. This pipeline integrates multiple state‑of‑the‑art tools to enable efficient and systematic protein engineering.
We established a quantitative framework for identifying mutation‑tolerant positions in therapeutic peptides using Shannon entropy as a selection criterion. This approach enables systematic protein engineering while minimizing the risk of disrupting protein structure and function.
Theoretical Foundation: Evolutionarily conserved positions are integral to protein structure and function, while variable positions represent sites where natural selection has tolerated mutations. Focusing engineering efforts on high‑entropy positions reduces the combinatorial search space while preserving the likelihood of functional variants.
Application to GLP‑1: Using this framework, we identified candidate positions in the GLP‑1 sequence for engineering enhanced receptor specificity—transforming an intractable combinatorial problem into a manageable, rational design challenge.
Through extensive troubleshooting and systematic optimization, we developed a decision‑tree methodology for diagnosing and resolving transformation failures. This framework provides future teams with a structured approach to protocol optimization.
Key Insight: While our specific experiments did not yield a fully optimized protocol—likely due to plasmid characteristics or equipment limitations—the framework enables rapid diagnosis and provides a roadmap for iterative optimization.